The estimated Net Worth of Kathy Ordonez is at least $27.9 Milion dollars as of 15 March 2024. Ms. Ordonez owns over 361,621 units of QuidelOrtho stock worth over $17,052,688 and over the last 13 years she sold QDEL stock worth over $10,682,230. In addition, she makes $155,820 as Independent Director at QuidelOrtho.
Kathy has made over 7 trades of the QuidelOrtho stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 361,621 units of QDEL stock worth $1,037,852 on 15 March 2024.
The largest trade she's ever made was exercising 361,621 units of QuidelOrtho stock on 15 March 2024 worth over $1,037,852. On average, Kathy trades about 20,683 units every 64 days since 2011. As of 15 March 2024 she still owns at least 380,216 units of QuidelOrtho stock.
You can see the complete history of Ms. Ordonez stock trades at the bottom of the page.
Kathy P. Ordonez serves as Independent Director of the Company. Ms. Ordoñez has more than 30 years of experience in the life sciences and diagnostics industry. She is currently on the Board of Directors for Pacific Biosciences, Inc., a life sciences company that develops, manufactures and sells long-read gene sequencing products. From October 2017 to October 2018, she also served at Pacific Biosciences as Chief Commercial Officer. Ms. Ordoñez also recently was Director (July 2014 through February 2017), non-Executive Chairman (2015), and Chief Executive Officer (2016) of RainDance Technologies, Inc., a life sciences company that specialized in droplet-based detection of genetic variations in cancer and infectious diseases until it was sold to Bio-Rad Laboratories, Inc. in February 2017. Prior to this, Ms. Ordoñez was a Senior Vice President for Quest Diagnostics, Inc., a leading provider of diagnostic services and information, from May 2011 to June 2013 where she held the lead positions in Discovery and Development (2011) and Diagnostic Solutions (2012). Her tenure at Quest followed its acquisition, in 2011, of Celera Corporation, a company that discovered and developed genetic tests. Ms. Ordoñez was Chief Executive Officer of Celera Corporation (2008 - 2011) and founder and President of Celera Diagnostics (2000 - 2008). From 1985 until 2000, Ms. Ordoñez held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the polymerase chain reaction (PCR) technology to the research, diagnostic and forensic fields.
As the Independent Director of QuidelOrtho, the total compensation of Kathy Ordonez at QuidelOrtho is $155,820. There are 19 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of $4,168,770.
Kathy Ordonez is 69, she's been the Independent Director of QuidelOrtho since 2019. There are 1 older and 27 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.
Kathy's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck oraz Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
QuidelOrtho executives and other stock owners filed with the SEC include: